Skip to content

Study · Non-randomized trial · n = 8 · 1993

6 results

Octreotide reverses hyperinsulinemia and prevents hypoglycemia induced by sulfonylurea overdoses.

Boyle PJ, Justice K, Krentz AJ, Nagy RJ, Schade DS

The Journal of clinical endocrinology and metabolism1 Mar 1993Cited by 63 (Europe PMC)

PMID8445035 (opens in a new tab)DOI10.1210/jcem.76.3.8445035 (opens in a new tab)PepBankPUB-08445035
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In subjects after glipizide overdose, insulin concentrations were 4-5 times greater with dextrose alone than with octreotide (P < 0.01).

    In plain wordsAfter glipizide overdose, subjects had lower insulin concentrations with octreotide than with dextrose alone.

    Peptide
    Octreotide
    Outcome
    DecreaseInsulin concentrations versus dextrose
    Study

    n = 8

    Comparator
    Dextrose alone
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    30 ng/kg.min · intravenousAs given in this study (human).

    Measurements

    Insulin concentration ratio versus octreotide
    4 to 5 fold
    dextrose alone or with diazoxide versus octreotide

    Source sentences

    Summary
    Insulin concentrations were 4-5 times greater with dextrose alone or in combination with diazoxide than with octreotide (P < 0.01).
    2 context sentences
    Summary · context
    Eight normal subjects received glipizide (1.45 mg/kg) on three occasions.
    Summary · context
    Within 3 h, all subjects became hypoglycemic (< 50 mg/dL) and were initially treated with 50% dextrose followed by 1) dextrose infusion, 2) octreotide (30 ng/kg.min, iv), or 3) diazoxide (300 mg, iv, every 4 h).
  2. 02HumanNon-randomized trialEfficacy outcome

    In subjects after glipizide overdose, insulin concentrations were 4-5 times greater with diazoxide plus dextrose than with octreotide (P < 0.01).

    In plain wordsAfter glipizide overdose, subjects had lower insulin concentrations with octreotide than with diazoxide plus dextrose.

    Peptide
    Octreotide
    Outcome
    DecreaseInsulin concentrations versus diazoxide
    Study

    n = 8

    Comparator
    Diazoxide with dextrose
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    30 ng/kg.min · intravenousAs given in this study (human).

    Measurements

    Insulin concentration ratio versus octreotide
    4 to 5 fold
    dextrose alone or with diazoxide versus octreotide

    Source sentences

    Summary
    Insulin concentrations were 4-5 times greater with dextrose alone or in combination with diazoxide than with octreotide (P < 0.01).
    2 context sentences
    Summary · context
    Eight normal subjects received glipizide (1.45 mg/kg) on three occasions.
    Summary · context
    Within 3 h, all subjects became hypoglycemic (< 50 mg/dL) and were initially treated with 50% dextrose followed by 1) dextrose infusion, 2) octreotide (30 ng/kg.min, iv), or 3) diazoxide (300 mg, iv, every 4 h).
  3. 03HumanNon-randomized trialEfficacy outcome

    In subjects after glipizide overdose, octreotide reduced dextrose requirements compared with diazoxide (P < 0.0001).

    In plain wordsAfter glipizide overdose, subjects needed less dextrose with octreotide than with diazoxide.

    Peptide
    Octreotide
    Outcome
    DecreaseDextrose requirements versus diazoxide
    Study

    n = 8

    Comparator
    Diazoxide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    30 ng/kg.min · intravenousAs given in this study (human).

    Source sentences

    Summary
    Dextrose requirements during diazoxide or dextrose alone were not different, but were both greater than those during octreotide treatment (P < 0.0001).
    2 context sentences
    Summary · context
    Eight normal subjects received glipizide (1.45 mg/kg) on three occasions.
    Summary · context
    Within 3 h, all subjects became hypoglycemic (< 50 mg/dL) and were initially treated with 50% dextrose followed by 1) dextrose infusion, 2) octreotide (30 ng/kg.min, iv), or 3) diazoxide (300 mg, iv, every 4 h).
  4. 04HumanNon-randomized trialEfficacy outcome

    In subjects after glipizide overdose, octreotide reduced dextrose requirements compared with dextrose alone (P < 0.0001).

    In plain wordsAfter glipizide overdose, subjects needed less dextrose with octreotide than with dextrose alone.

    Peptide
    Octreotide
    Outcome
    DecreaseDextrose requirements versus dextrose alone
    Study

    n = 8

    Comparator
    Dextrose alone
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    30 ng/kg.min · intravenousAs given in this study (human).

    Source sentences

    Summary
    Dextrose requirements during diazoxide or dextrose alone were not different, but were both greater than those during octreotide treatment (P < 0.0001).
    2 context sentences
    Summary · context
    Eight normal subjects received glipizide (1.45 mg/kg) on three occasions.
    Summary · context
    Within 3 h, all subjects became hypoglycemic (< 50 mg/dL) and were initially treated with 50% dextrose followed by 1) dextrose infusion, 2) octreotide (30 ng/kg.min, iv), or 3) diazoxide (300 mg, iv, every 4 h).
  5. 05HumanNon-randomized trialEfficacy outcome

    After glipizide overdose, glucose remained above 3.6 mmol/L (65 mg/dL) for 4 h after treatment cessation in six of eight octreotide subjects.

    In plain wordsAfter glipizide overdose, six of eight octreotide subjects maintained glucose above 3.6 mmol/L for 4 hours after treatment stopped.

    Peptide
    Octreotide
    Outcome
    Not applicableGlucose after treatment cessation
    Study

    n = 8

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    30 ng/kg.min · intravenousAs given in this study (human).

    Measurements

    Subjects with glucose above 3.6 mmol/L (65 mg/dL) for remaining 4 h
    6 subjects
    octreotide, of 8 subjects

    Source sentences

    Summary
    Glucose levels remained above 3.6 mmol/L (65 mg/dL) in six of eight subjects receiving octreotide for the remaining 4 h.
    3 context sentences
    Summary · context
    All therapies were stopped at 13 h.
    Summary · context
    Eight normal subjects received glipizide (1.45 mg/kg) on three occasions.
    Summary · context
    Within 3 h, all subjects became hypoglycemic (< 50 mg/dL) and were initially treated with 50% dextrose followed by 1) dextrose infusion, 2) octreotide (30 ng/kg.min, iv), or 3) diazoxide (300 mg, iv, every 4 h).
  6. 06HumanNon-randomized trialEfficacy outcome

    After glipizide overdose, octreotide reduced exogenous glucose need and eliminated it in four of eight subjects.

    In plain wordsAfter glipizide overdose, octreotide reduced glucose treatment needs and eliminated them in four of eight subjects.

    Peptide
    Octreotide
    Outcome
    DecreaseElimination of exogenous glucose need
    Study

    n = 8

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    30 ng/kg.min · intravenousAs given in this study (human).

    Measurements

    Subjects with need for exogenous glucose eliminated
    4 subjects
    octreotide, of 8 subjects

    Source sentences

    Summary
    Overall, octreotide reduced and in four of eight subjects entirely eliminated the need for exogenous glucose after a large overdose of glipizide.
    2 context sentences
    Summary · context
    Eight normal subjects received glipizide (1.45 mg/kg) on three occasions.
    Summary · context
    Within 3 h, all subjects became hypoglycemic (< 50 mg/dL) and were initially treated with 50% dextrose followed by 1) dextrose infusion, 2) octreotide (30 ng/kg.min, iv), or 3) diazoxide (300 mg, iv, every 4 h).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 1NCT02237053

Effects of Glucagon Administration on Energy Expenditure

AdventHealth Translational Research Instituten = 6Sept 2014 to Jun 2016

Hyperglucagonemia · Obesity

Trial pageClinicalTrials.govUpdated 26 Apr 2018

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.